Concepedia

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

Padmanee Sharma, Margaret K. Callahan, Petri Bono, Joseph W. Kim, Pavlina Spiliopoulou, Emiliano Calvo, Rathi N. Pillai, Patrick A. Ott, Filippo de Braud, Michael A. Morse,

The Lancet Oncology · 2016 · 685 citations · 29 references

DOIFull text

Open access

Concepts

References

29

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text

, , +17

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text

, , +15

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.9K citations · Full text

, , +17

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

Caroline Robert, Georgina V. Long, Benjamin Brady et al. · New England Journal of Medicine · 2014 · 5.4K citations · Full text

, , +14